The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials
The American Journal of Clinical Nutrition · 2024-02 · 119 (2) · 496-510
DOI: 10.1016/j.ajcnut.2023.10.030 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The American Journal of Clinical Nutrition, 2024-02. Verfasst von Jhalok Ronjan Talukdar und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Inulin, Cardiovascular Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: National Honey Board, United Soybean Board, Canadian Society of Endocrinology and Metabolism.
Abstract (Originalsprache)
BACKGROUND: Inulin-type fructans (ITF) are the leading prebiotics in the market. Available evidence provides conflicting results regarding the beneficial effects of ITF on cardiovascular disease risk factors. OBJECTIVES: This study aimed to evaluate the effects of ITF supplementation on cardiovascular disease risk factors in adults. METHODS: We searched MEDLINE, EMBASE, Emcare, AMED, CINAHL, and the Cochrane Library databases from inception through May 15, 2022. Eligible randomized controlled trials (RCTs) administered ITF or placebo (for example, control, foods, diets) to adults for ≥2 weeks and reported one or more of the following: low, very-low, or high-density lipoprotein cholesterol (LDL-C, VLDL-C, HDL-C); total cholesterol; apolipoprotein A1 or B; triglycerides; fasting blood glucose; body mass index; body weight; waist circumference; waist-to-hip ratio; systolic or diastolic blood pressure; or hemoglobin A1c. Two reviewers independently and in duplicate screened studies, extracted data, and assessed risk of bias. We pooled data using random-effects model, and assessed the certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development and Evaluation approach. RESULTS: We identified 1767 studies and included 55 RCTs with 2518 participants in meta-analyses. The pooled estimate showed that ITF supplementation reduced LDL-C [mean difference (MD) -0.14 mmol/L, 95% confidence interval (95% CI: -0.24, -0.05), 38 RCTs, 1879 participants, very low CoE], triglycerides (MD -0.06 mmol/L, 95% CI: -0.12, -0.01, 40 RCTs, 1732 participants, low CoE), and body weight (MD -0.97 kg, 95% CI: -1.28, -0.66, 36 RCTs, 1672 participants, low CoE) but little to no significant effect on other cardiovascular disease risk factors. The effects were larger when study duration was ≥6 weeks and in pre-obese and obese participants. CONCLUSION: ITF may reduce low-density lipoprotein, triglycerides, and body weight. However, due to low to very low CoE, further well-designed and executed trials are needed to confirm these effects. PROSPERO REGISTRATION NUMBER: CRD42019136745.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
- Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Blavatnik Institute, Harvard Medical School, Boston, MA, United States.
- Faculty of Law, Common Law Section, University of Ottawa, Ottawa, ON, Canada.
- Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
Förderung
- National Honey Board
- United Soybean Board
- Canadian Society of Endocrinology and Metabolism
- Institute for the Advancement of Food and Nutrition Sciences
- Ontario Research Foundation
- Canadian Institutes of Health Research
- Flax Council of Canada
- U.S. Department of Agriculture
Zitieren
APA
Talukdar, J. R., Cooper, M., Lyutvyn, L., Zeraatkar, D., Ali, R., Berbrier, R., Janes, S., Ha, V., Darling, P. B., Xue, M., Chu, A., Chowdhury, F., Harnack, H. E., Huang, L., Malik, M., Powless, J., Lavergne, F. V., Zhang, X., Ehrlich, S., …, & de Souza, R. J. (2024). The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials. The American Journal of Clinical Nutrition, 119(2), 496-510. https://doi.org/10.1016/j.ajcnut.2023.10.030
Vancouver
Talukdar JR, Cooper M, Lyutvyn L, Zeraatkar D, Ali R, Berbrier R, et al. The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials. The American Journal of Clinical Nutrition. 2024;119(2):496-510. doi:10.1016/j.ajcnut.2023.10.030
BibTeX
@article{Talukdar2024,
author = {Talukdar, Jhalok Ronjan and Cooper, Matthew and Lyutvyn, Lyuba and Zeraatkar, Dena and Ali, Rahim and Berbrier, Rachel and Janes, Sabrina and Ha, Vanessa and Darling, Pauline B and Xue, Mike and Chu, Alexandro and Chowdhury, Fariha and Harnack, Hope E and Huang, Louise and Malik, Mikail and Powless, Jacqui and Lavergne, Florence V and Zhang, Xuehong and Ehrlich, Shelley and Jenkins, David Ja and Sievenpiper, John L and Banfield, Laura and Mbuagbaw, Lawrence and de Souza, Russell J},
title = {The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials},
journal = {The American Journal of Clinical Nutrition},
year = {2024},
volume = {119},
number = {2},
pages = {496--510},
doi = {10.1016/j.ajcnut.2023.10.030}
}
EUVIMED